| Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies RE Chen, X Zhang, JB Case, ES Winkler, Y Liu, LA VanBlargan, J Liu, ... Nature medicine 27 (4), 717-726, 2021 | 909 | 2021 |
| Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study P Deepak, W Kim, MA Paley, M Yang, AB Carvidi, EG Demissie, ... Annals of internal medicine 174 (11), 1572-1585, 2021 | 283 | 2021 |
| T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study P Deepak, H Sifuentes, M Sherid, D Stobaugh, Y Sadozai, ED Ehrenpreis Official journal of the American College of Gastroenterology| ACG 108 (1 …, 2013 | 250 | 2013 |
| Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis A Jena, S Mishra, P Deepak, P Kumar-M, A Sharma, YI Patel, ... Autoimmunity reviews 21 (1), 102927, 2022 | 167 | 2022 |
| Debaryomyces is enriched in Crohn’s disease intestinal tissue and impairs healing in mice U Jain, AM Ver Heul, S Xiong, MH Gregory, EG Demers, JT Kern, CW Lai, ... Science 371 (6534), 1154-1159, 2021 | 152 | 2021 |
| Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2 P Deepak, W Kim, MA Paley, M Yang, AB Carvidi, AA El-Qunni, A Haile, ... MedRxiv, 2021 | 145 | 2021 |
| Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn's disease P Deepak, JG Fletcher, JL Fidler, JM Barlow, SP Sheedy, AB Kolbe, ... Official journal of the American College of Gastroenterology| ACG 111 (7 …, 2016 | 142 | 2016 |
| Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk D Parakkal, H Sifuentes, R Semer, ED Ehrenpreis European journal of gastroenterology & hepatology 23 (12), 1150, 2011 | 128 | 2011 |
| Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System P Deepak, DJ Stobaugh, M Sherid, H Sifuentes, ED Ehrenpreis Alimentary pharmacology & therapeutics 38 (4), 388-396, 2013 | 106 | 2013 |
| SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies M Diamond, R Chen, X Xie, J Case, X Zhang, L VanBlargan, Y Liu, J Liu, ... Research square, 2021 | 85 | 2021 |
| Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility A Sazonovs, CR Stevens, GR Venkataraman, K Yuan, B Avila, MT Abreu, ... Nature genetics 54 (9), 1275-1283, 2022 | 84 | 2022 |
| The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits ED Ehrenpreis, P Deepak, H Sifuentes, R Devi, H Du, JB Leikin Official journal of the American College of Gastroenterology| ACG 108 (6 …, 2013 | 82 | 2013 |
| Ustekinumab is effective for the treatment of Crohn’s disease of the pouch in a multicenter cohort KN Weaver, M Gregory, G Syal, P Hoversten, SB Hicks, D Patel, ... Inflammatory bowel diseases 25 (4), 767-774, 2019 | 79 | 2019 |
| Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis P Deepak, QA Alayo, A Khatiwada, B Lin, M Fenster, C Dimopoulos, ... Clinical Gastroenterology and Hepatology 19 (8), 1592-1601. e3, 2021 | 78 | 2021 |
| Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug … P Deepak, DJ Stobaugh, ED Ehrenpreis Journal of Gastrointestinal & Liver Diseases 22 (3), 2013 | 73 | 2013 |
| Ustekinumab and anti-interleukin-23 agents in Crohn's disease P Deepak, WJ Sandborn Gastroenterology Clinics 46 (3), 603-626, 2017 | 68 | 2017 |
| Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines … MR McKenna, DJ Stobaugh, P Deepak Journal of Gastrointestinal & Liver Diseases 23 (3), 2014 | 66 | 2014 |
| Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a multicenter US cohort M Gregory, KN Weaver, P Hoversten, SB Hicks, D Patel, MA Ciorba, ... Inflammatory bowel diseases 25 (9), 1569-1576, 2019 | 65 | 2019 |
| Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy P Deepak, EV Loftus Jr Drug design, development and therapy, 3685-3698, 2016 | 53 | 2016 |
| The role of the radiologist in determining disease severity in inflammatory bowel diseases P Deepak, JE Axelrad, AN Ananthakrishnan Gastrointestinal Endoscopy Clinics 29 (3), 447-470, 2019 | 51 | 2019 |
Eli D. EhrenpreisClinical Associate Professor of Medicine, University of Chicago在 gipharm.net 的电子邮件经过验证
